Polysarcosine-Vitamin E Micelles for PEG-Free Solubility
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing vitamin E derivatives, such as TPGS, suffer from poor water solubility, toxicity, and immunogenicity due to the inclusion of PEG, leading to reduced efficacy and stability in drug delivery systems.
Innovation Solution
Development of polysarcosine-vitamin E derivatives that are biodegradable, non-immunogenic, and amphiphilic, forming self-assembled particles like micelles to encapsulate active agents, offering improved solubility and antioxidant properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If PEG is included in vitamin E derivatives (TPGS) to improve water solubility, then solubility is improved, but immunogenicity and toxicity increase
Solution Approach 1:
The invention changes the chemical structure parameters by replacing PEG chains with polysarcosine chains in the vitamin E derivative structure. This structural parameter change maintains amphiphilic properties and water solubility while eliminating the immunogenicity and toxicity associated with PEG, as polysarcosine is biodegradable and non-immunogenic.
Solution Approach 2:
The invention creates a composite material structure by combining vitamin E core with polysarcosine chains to form amphiphilic derivatives. This composite approach integrates the antioxidant properties of vitamin E with the biocompatibility and solubility enhancement of polysarcosine, achieving a material that overcomes the limitations of PEG-based derivatives.
2Duration of action of moving object
If PEG is used to achieve stealth properties and prolonged circulation time, then circulation time is improved, but accelerated blood clearance phenomenon occurs
Solution Approach 1:
The invention extracts and removes the PEG component from the vitamin E derivative structure, eliminating the source of the accelerated blood clearance phenomenon. By replacing PEG with polysarcosine chains, the derivative maintains solubility and biocompatibility without triggering the immunogenic response that causes ABC phenomenon and reduced circulation time consistency.
3Stability of the object's composition
If vitamin E is esterified with acetate or succinate to improve shelf life, then stability is improved, but water solubility deteriorates
Solution Approach 1:
The invention merges the stability-enhancing esterification approach with solubility-enhancing amphiphilic structure design. By combining vitamin E core with polysarcosine chains through ester or amide linkages, the derivative achieves both improved shelf life (through stable esterification) and enhanced water solubility (through amphiphilic structure with hydrophilic polysarcosine chains).
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polysarcosine-vitamin E derivatives demonstrate enhanced solubility and accumulation in the epidermis, overcoming the limitations of TPGS for skin delivery applications while maintaining therapeutic efficacy.
Implementation Method 1
forming self-assembled particles like micelles to encapsulate active agents
Implementation Method 2
The polysarcosine-vitamin E derivatives of the invention are amphiphilic. They comprise a hydrophilic polar head portion, the PSar-based moiety, and a hydrophobic part, the vitamin E-based moiety.
Implementation Method 3
the polysarcosine-vitamin E derivatives demonstrate enhanced solubility and accumulation in the epidermis
Data Source
Figure 1A~1B
Figure 2
AI summary
It relates to a polymer comprising a repeating sarcosine-based unit which is covalently attached directly or through a linker to a vitamin E-based moiety, acceptable salts, stereoisomers and mixtures thereof, and to conjugates of formula (II) comprising these polymers. Nutraceutical, pharmaceutical, diagnostic and cosmetic compositions comprising the polymers and/or the conjugates of formula (II), together with acceptable excipients or carriers are also provided, as well as self-assembled particles comprising the polymers and/or the conjugates of formula (II) and optionally agents encapsulated within the self-assembled particles. It also relates to the use of the polysarcosine-vitamin E derivatives and/or their conjugates in medicine and diagnostics, and as solubilizers, absorption and permeation enhancers, emulsifiers or surface stabilizers.